Analytical Data
-
Gene name
LIV-1/SLC39A6 Protein-VLP
- Application
-
Alternative Names
SLC39A6; LIV-1; ZIP6; Zinc transporter ZIP6; ZIP-6
-
Species
Human
-
Source
HEK293
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13433
-
Expression Region
F29-F755
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LIV-1, also known as SLC39A6, is a member of the ZIP (Zinc Transporter) family of proteins and plays a pivotal role in zinc homeostasis within cells. Its expression is notably upregulated in various types of cancers, particularly breast cancer, where it is associated with poor prognosis and tumor progression. This has prompted extensive research into LIV-1 as a potential biomarker and therapeutic target. Recent studies have demonstrated that LIV-1 facilitates Zinc transport, which is crucial for various cellular processes, including cell proliferation, apoptosis, and immune response. The recombinant protein of LIV-1/SLC39A6, produced in Virus-Like Particles (VLP), offers a promising avenue for further investigation. The use of VLPs enhances the stability and immunogenicity of the recombinant protein, paving the way for novel therapeutic and diagnostic applications. Understanding the interactions and functions of LIV-1 in vivo can facilitate the development of targeted therapies aimed at inhibiting its function in tumors, thereby providing a potential strategy for cancer treatment. Moreover, insights gained from studying LIV-1 protein within VLPs could elucidate its biological mechanisms and contributions to malignancy, ultimately leading to breakthroughs in cancer management.
